Chad Pecot, MD

@ChadPecot

Cancer Killer | Engineering RNA medicines to End Cancer | Potentially sarcastic | Honey-badger

Outside the box

Joined June 2020

291Following

2KFollowers

Pinned

Chad Pecot, MD@ChadPecot · Jun 20

Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. KRAS G12V mutations are the 2nd most common KRAS mutation in cancer, and there are still no approved inhibitors in the clinic. We address two major challenges…

ChadPecot's tweet image. Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor.

KRAS G12V mutations are the 2nd most common KRAS mutation in cancer, and there are still no approved inhibitors in the clinic.

We address two major challenges…

351

122

37.0K

Chad Pecot, MD@ChadPecot · Jul 9

Due to a high volume of emails, I am no longer responding. 🫶

661

Chad Pecot, MD Retweeted

Lior Pachter@lpachter · Jul 1

This week in academia, a not so short🧵... 1. Staff reductions and other cost cutting measures coming to Brown University highereddive.com/news/brown-uni…

104

265

127

116.0K

Chad Pecot, MD Retweeted

UNC Lineberger@UNC_Lineberger · Jun 23

.@ChadPecot, MD, and colleagues have demonstrated that a uniquely engineered drug that zeroes in on a mutated gene called KRAS G12V could potentially stop KRAS-dependent cancers in their tracks. unclineberger.org/news/uniquely-…

353

Chad Pecot, MD Retweeted

Cancer Cell@Cancer_Cell · Jun 19

Online Now: A first-in-class EGFR-directed KRAS G12V selective inhibitor dlvr.it/TLS4CJ

143

16.0K